Verisante Technology, Inc.
TSX VENTURE : VRS
PINK SHEETS : VRSEF

Verisante Technology, Inc.

February 15, 2011 10:00 ET

Verisante Featured on Business Television (BTV); Announces Conference Attendance

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 15, 2011) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTC:VRSEF) (the "Company" or "Verisante") announces that the Company will be featured on Business Television (BTV) to air on February 19 and 20, 2011. BTV, a half-hour business program, has been profiling innovative companies in North America every week for the past 13 years. Verisante will air on BTV on the following channels:

In Canada

  • BNN on Saturday, February 19 at 8 pm (EST) and Sunday, February 20 at 9:30 am (EST)
  • Bell Express VU on Saturday, February 19 at 8 pm (EST) and Sunday, February 20 at 9:30 am (EST)

In the United States

  • Fox Business News Net on Sunday, February 20 at 5 pm (EST)
  • America One on Saturday, February 19 at 10:30 am (EST) (www.amerciaone.com)
  • Biz Television Network on Saturday, February 19 and Sunday, February 20 at 8 pm and midnight (CST), and Thursday, December 23 at 9 am and midnight (CST) (www.biztelevision.com)

A link to the entire feature will be available on the Company's website after the broadcast.

Conference Attendance

Verisante President and CEO Thomas Braun will be making presentations at three conferences between February 22 and March 3, 2011:

  • Investment in Innovation In(3) West in Las Vegas, NV, from February 22-24;
  • BioPartnering North America in Vancouver, BC from February 27-March 1; and
  • Life Science Innovation Northwest in Seattle, WA from March 2-3, 2011.

"In3, BioPartnering North America and Life Science Innovation Northwest provide us with the opportunity to continue increasing awareness of Verisante's innovative cancer-detection technology within the life sciences industry," said Braun.

About Verisante

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.

About the BC Cancer Agency

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency (www.bccancer.bc.ca).

About The Skin Care Centre at Vancouver General Hospital

The Skin Care Centre at VGH is affiliated with the UBC Department of Dermatology and Skin Sciences. It is a national centre of excellence uniting clinical care, research, and education. The Centre sees over 20,000 patients annually in general and subspecialty dermatology clinics, and runs the country's busiest phototherapy centre. A critical component of the Skin Care Centre at VGH is its comprehensive and aggressive program dedicated to exploring all aspects of skin cancer, encompassing treatment, clinical, and basic science research (www.skincarecentre.ca).

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information